|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Further studies of the V89L polymorphism may lead to better understanding of the etiology of pros</span>tate cancer metastases.
|
12042668 |
2002 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs5030739
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser-->Leu 217) and (Ala-->Thr 541).
|
12373607 |
2002 |
|
rs5030739
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The recently identified prostate cancer susceptibility gene ELAC2 ( HPC2) harbors two common missense variants, a serine to leucine substitution at residue 217 (Leu217) and an alanine to threonine substitution at residue 541 (Thr541).
|
12522685 |
2002 |
|
rs4792311
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The recently identified prostate cancer susceptibility gene ELAC2 ( HPC2) harbors two common missense variants, a serine to leucine substitution at residue 217 (Leu217) and an alanine to threonine substitution at residue 541 (Thr541).
|
12522685 |
2002 |
|
rs4792311
|
|
|
0.080 |
GeneticVariation |
BEFREE |
To test the hypothesis that variation in the putative prostate cancer susceptibility gene ELAC2 contributes to the elevated risk of prostate cancer in Afro-Caribbean males from Tobago, we genotyped the S217L and A514T polymorphisms, previously reported to be associated with prostate cancer risk in a large sample of cases and controls.
|
12384782 |
2002 |
|
rs4792311
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser-->Leu 217) and (Ala-->Thr 541).
|
12373607 |
2002 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs1034866440
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs10941112
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Furthermore, the AMACR sequence variants strongly cosegregate with CaP in HPC families (log of odds = 3.78; P = 0.00006), especially in the subset of families whose probands carry the "A-A" haplotype of M9V and D175G (log of odds = 4.34; P = 0.000008).
|
12438241 |
2002 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs137852569
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |
|
rs864622007
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs864622007
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs1047303
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Men with the variant genotypes at either B1-N367T or B2-c7519g had a significantly higher risk to develop prostate cancer, especially the hereditary type of prostate cancer.
|
11912155 |
2002 |
|
rs45609334
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Men with the variant genotypes at either B1-N367T or B2-c7519g had a significantly higher risk to develop prostate cancer, especially the hereditary type of prostate cancer.
|
11912155 |
2002 |
|
rs2066479
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data are consistent with a plausible role of the G289S SNP in prostate cancer susceptibility.
|
12210481 |
2002 |
|
rs749198869
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Men with the variant genotypes at either B1-N367T or B2-c7519g had a significantly higher risk to develop prostate cancer, especially the hereditary type of prostate cancer.
|
11912155 |
2002 |
|
rs757284769
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To test the hypothesis that variation in the putative prostate cancer susceptibility gene ELAC2 contributes to the elevated risk of prostate cancer in Afro-Caribbean males from Tobago, we genotyped the S217L and A514T polymorphisms, previously reported to be associated with prostate cancer risk in a large sample of cases and controls.
|
12384782 |
2002 |
|
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, RNase L(R462Q) was deficient in causing apoptosis in response to 2-5A consistent with its possible role in prostate cancer development.
|
14583476 |
2003 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The V allele of the V89L polymorphism in the SRD5A2 gene may dominantly increase the risk of prostate cancer.
|
12771801 |
2003 |